M&G PLC

Explore how M&G PLC’s 2026 filing reveals hidden voting‑rights gaps and timed Vesuvius share sales, spotlighting governance and market‑impact risks for investors.

Discover how M&G PLC’s half‑year report showcases stable returns, disciplined risk, and digital growth in life, health insurance and asset management.

Explore how M&G PLC’s modest share gains mask deeper issues—earnings driven by fees, high leverage, and hidden corporate actions—challenging its “strong performer” label in the FTSE 100.

On 3 Aug 2026, M&G plc disclosed its share‑capital structure and a modest EasyJet equity stake, underscoring disciplined capital management and strict regulatory compliance.

Discover why M&G PLC’s 1% stake in Tate & Lyle could signal strategic moves or hidden market influence—insights that matter for investors and industry players.

Explore how M&G’s 1% stake and block sales in Tate & Lyle reveal hidden risks, lack of derivatives, and governance gaps that could impact investors and communities.

Neutral‑valued M&G PLC shares match eyeQ forecasts amid tightening rates, while Prudential’s aggressive share‑buyback boosts capital ratios and ROE—key insights for investors seeking macro‑sensitive strategies.

Explore how M&G’s latest UK‑LSE filings reveal strategic stake‑shifts in Tate & Lyle, Integrated Diagnostics, and Oxford Biomedica, and the hidden implications for shareholders and governance.

Explore how M&G’s 1.8% passive stake in EasyJet and modest senior‑manager share purchases reflect broader UK firm share‑holding strategies and regulatory compliance.

Discover how M&G plc’s new share‑incentive plan, SS&C partnership and performance review reinforce governance, operational efficiency and shareholder value.